<DOC>
	<DOCNO>NCT01118234</DOCNO>
	<brief_summary>The purpose study evaluate ability Rituximab maintenance therapy prolong progression free survival patient chronic lymphocytic leukemia , respond Rituximab induction therapy .</brief_summary>
	<brief_title>Rituximab Versus Observation Maintenance Therapy Chronic Lymphocytic Leukemia ( Chronic Lymphocytic Leukemia )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>BCLL Age &gt; 18 ECOG performance status 02 Previous Rituximab contain induction treatment CLL 1st 2nd line Patient must complete remission partial remission induction treatment contain rituximab ANC ( absolute neutrophil count ) &gt; 1,0 x 10e9 /L Life expectancy &gt; 6 month PatientÂ´s write informed consent Patient use reliable mean contraception duration treatment include 2 month thereafter Active uncontrolled bacterial , viral fungal infection Significantly reduce organ function bone marrow dysfunction due CLL creatinine clearance 30mL/min Patients history malignancy within 2 year prior study entry Patients history severe cardiac disease Other know comorbidity potential dominate survival Transformation aggressive Bcell malignancy Hypersensitivity anaphylactic reaction humanize monoclonal antibody apply drug Medical condition require prolong ( &gt; 1 month ) use oral corticosteroid Pregnant breast feed woman Any coexist medical psychological condition would preclude participation study compromise ability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>CLL</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Maintenance</keyword>
</DOC>